3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Melanoma
5
Neoplasm Metastasis
3
Colorectal Neoplasms
3
Solid Tumors Harboring a BRAF V600 Mutation
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Lung Neoplasms
1
Gastrointestinal Neoplasms
1
Disease Progression
1
Digestive System Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Advanced BRAF Mutant Cancers
1
Interventions
Fluorouracil
8
Oxaliplatin
7
Leucovorin
6
Irinotecan
6
Gemcitabine
5
fludarabine
3
aldesleukin
3
Pemetrexed
3
Nivolumab
3
Cyclophosphamide
3
Cetuximab
3
Capecitabine
3
5,10-methylenetetrahydrofolic acid
3
dehydroftorafur
2
cobimetinib
2
Specimen Handling
2
Panitumumab
2
Interleukin-2
2
Docetaxel
2
Bevacizumab
2
130-nm albumin-bound paclitaxel
2
tivozanib
1
sodium propionate
1
rucaparib
1
rilotumumab
1
repotrectinib
1
regorafenib
1
pralsetinib
1
pertuzumab
1
pembrolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Gastrointestinal Neoplasms
×
encorafenib
×
Clear all
NCT05039177
2026-03-25
HERKULES-3
Erasca, Inc.
Phase 1/2
Completed
101 enrolled